Global mRNA Vaccine Raw Materials Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI11242491

Publication Date:

November 7, 2024

Pages:

133

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The development and production of mRNA vaccines is relatively simple, scalable, and extremely rapid. mRNA is produced in vitro through an enzymatic process without the need to remove cells or host cell proteins. This simplified production process allows GMP facilities to be converted to produce new protein targets in a very short period of time, with only minimal changes to the process and formulation.
The global mRNA Vaccine Raw Materials market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥渕RNA Vaccine Raw Materials Industry Forecast鈥� looks at past sales and reviews total world mRNA Vaccine Raw Materials sales in 2022, providing a comprehensive analysis by region and market sector of projected mRNA Vaccine Raw Materials sales for 2023 through 2029. With mRNA Vaccine Raw Materials sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Vaccine Raw Materials industry.
This Insight Report provides a comprehensive analysis of the global mRNA Vaccine Raw Materials landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on mRNA Vaccine Raw Materials portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global mRNA Vaccine Raw Materials market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Vaccine Raw Materials and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Vaccine Raw Materials.
United States market for mRNA Vaccine Raw Materials is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for mRNA Vaccine Raw Materials is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for mRNA Vaccine Raw Materials is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key mRNA Vaccine Raw Materials players cover Thermo Fisher Scientific Inc., Danaher Corporation, Kaneka Eurogentec S.A., BioSpring, GenScript, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Vaccine Raw Materials market by product type, application, key players and key regions and countries.
Segmentation by Type:
Plasmid DNA (pDNA)
Enzyme
Other
Segmentation by Application:
(non-replicating) mRNA vaccine
(self-amplifying) mRNA vaccine
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Plasmid DNA (pDNA)
Enzyme
Other
Segmentation by Application:
(non-replicating) mRNA vaccine
(self-amplifying) mRNA vaccine
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific Inc.
Danaher Corporation
Kaneka Eurogentec S.A.
BioSpring
GenScript
Aji Bio-Pharma
Merck KGaA
Aldevron
Hongene
WuXi Biologics
Asymchem
Cosychem
Novoprotein
Vazyme
Yeasen
KACTUS

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global mRNA Vaccine Raw Materials Market Size 2019-2030
2.1.2 mRNA Vaccine Raw Materials Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for mRNA Vaccine Raw Materials by Country/Region, 2019, 2023 & 2030
2.2 mRNA Vaccine Raw Materials Segment by Type
2.2.1 Plasmid DNA (pDNA)
2.2.2 Enzyme
2.2.3 Other
2.3 mRNA Vaccine Raw Materials Market Size by Type
2.3.1 mRNA Vaccine Raw Materials Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global mRNA Vaccine Raw Materials Market Size Market Share by Type (2019-2024)
2.4 mRNA Vaccine Raw Materials Segment by Application
2.4.1 (non-replicating) mRNA vaccine
2.4.2 (self-amplifying) mRNA vaccine
2.5 mRNA Vaccine Raw Materials Market Size by Application
2.5.1 mRNA Vaccine Raw Materials Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global mRNA Vaccine Raw Materials Market Size Market Share by Application (2019-2024)
3 mRNA Vaccine Raw Materials Market Size by Player
3.1 mRNA Vaccine Raw Materials Market Size Market Share by Player
3.1.1 Global mRNA Vaccine Raw Materials Revenue by Player (2019-2024)
3.1.2 Global mRNA Vaccine Raw Materials Revenue Market Share by Player (2019-2024)
3.2 Global mRNA Vaccine Raw Materials Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 mRNA Vaccine Raw Materials by Region
4.1 mRNA Vaccine Raw Materials Market Size by Region (2019-2024)
4.2 Global mRNA Vaccine Raw Materials Annual Revenue by Country/Region (2019-2024)
4.3 Americas mRNA Vaccine Raw Materials Market Size Growth (2019-2024)
4.4 APAC mRNA Vaccine Raw Materials Market Size Growth (2019-2024)
4.5 Europe mRNA Vaccine Raw Materials Market Size Growth (2019-2024)
4.6 Middle East & Africa mRNA Vaccine Raw Materials Market Size Growth (2019-2024)
5 Americas
5.1 Americas mRNA Vaccine Raw Materials Market Size by Country (2019-2024)
5.2 Americas mRNA Vaccine Raw Materials Market Size by Type (2019-2024)
5.3 Americas mRNA Vaccine Raw Materials Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC mRNA Vaccine Raw Materials Market Size by Region (2019-2024)
6.2 APAC mRNA Vaccine Raw Materials Market Size by Type (2019-2024)
6.3 APAC mRNA Vaccine Raw Materials Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe mRNA Vaccine Raw Materials Market Size by Country (2019-2024)
7.2 Europe mRNA Vaccine Raw Materials Market Size by Type (2019-2024)
7.3 Europe mRNA Vaccine Raw Materials Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa mRNA Vaccine Raw Materials by Region (2019-2024)
8.2 Middle East & Africa mRNA Vaccine Raw Materials Market Size by Type (2019-2024)
8.3 Middle East & Africa mRNA Vaccine Raw Materials Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global mRNA Vaccine Raw Materials Market Forecast
10.1 Global mRNA Vaccine Raw Materials Forecast by Region (2025-2030)
10.1.1 Global mRNA Vaccine Raw Materials Forecast by Region (2025-2030)
10.1.2 Americas mRNA Vaccine Raw Materials Forecast
10.1.3 APAC mRNA Vaccine Raw Materials Forecast
10.1.4 Europe mRNA Vaccine Raw Materials Forecast
10.1.5 Middle East & Africa mRNA Vaccine Raw Materials Forecast
10.2 Americas mRNA Vaccine Raw Materials Forecast by Country (2025-2030)
10.2.1 United States Market mRNA Vaccine Raw Materials Forecast
10.2.2 Canada Market mRNA Vaccine Raw Materials Forecast
10.2.3 Mexico Market mRNA Vaccine Raw Materials Forecast
10.2.4 Brazil Market mRNA Vaccine Raw Materials Forecast
10.3 APAC mRNA Vaccine Raw Materials Forecast by Region (2025-2030)
10.3.1 China mRNA Vaccine Raw Materials Market Forecast
10.3.2 Japan Market mRNA Vaccine Raw Materials Forecast
10.3.3 Korea Market mRNA Vaccine Raw Materials Forecast
10.3.4 Southeast Asia Market mRNA Vaccine Raw Materials Forecast
10.3.5 India Market mRNA Vaccine Raw Materials Forecast
10.3.6 Australia Market mRNA Vaccine Raw Materials Forecast
10.4 Europe mRNA Vaccine Raw Materials Forecast by Country (2025-2030)
10.4.1 Germany Market mRNA Vaccine Raw Materials Forecast
10.4.2 France Market mRNA Vaccine Raw Materials Forecast
10.4.3 UK Market mRNA Vaccine Raw Materials Forecast
10.4.4 Italy Market mRNA Vaccine Raw Materials Forecast
10.4.5 Russia Market mRNA Vaccine Raw Materials Forecast
10.5 Middle East & Africa mRNA Vaccine Raw Materials Forecast by Region (2025-2030)
10.5.1 Egypt Market mRNA Vaccine Raw Materials Forecast
10.5.2 South Africa Market mRNA Vaccine Raw Materials Forecast
10.5.3 Israel Market mRNA Vaccine Raw Materials Forecast
10.5.4 Turkey Market mRNA Vaccine Raw Materials Forecast
10.6 Global mRNA Vaccine Raw Materials Forecast by Type (2025-2030)
10.7 Global mRNA Vaccine Raw Materials Forecast by Application (2025-2030)
10.7.1 GCC Countries Market mRNA Vaccine Raw Materials Forecast
11 Key Players Analysis
11.1 Thermo Fisher Scientific Inc.
11.1.1 Thermo Fisher Scientific Inc. Company Information
11.1.2 Thermo Fisher Scientific Inc. mRNA Vaccine Raw Materials Product Offered
11.1.3 Thermo Fisher Scientific Inc. mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Thermo Fisher Scientific Inc. Main Business Overview
11.1.5 Thermo Fisher Scientific Inc. Latest Developments
11.2 Danaher Corporation
11.2.1 Danaher Corporation Company Information
11.2.2 Danaher Corporation mRNA Vaccine Raw Materials Product Offered
11.2.3 Danaher Corporation mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Danaher Corporation Main Business Overview
11.2.5 Danaher Corporation Latest Developments
11.3 Kaneka Eurogentec S.A.
11.3.1 Kaneka Eurogentec S.A. Company Information
11.3.2 Kaneka Eurogentec S.A. mRNA Vaccine Raw Materials Product Offered
11.3.3 Kaneka Eurogentec S.A. mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Kaneka Eurogentec S.A. Main Business Overview
11.3.5 Kaneka Eurogentec S.A. Latest Developments
11.4 BioSpring
11.4.1 BioSpring Company Information
11.4.2 BioSpring mRNA Vaccine Raw Materials Product Offered
11.4.3 BioSpring mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 BioSpring Main Business Overview
11.4.5 BioSpring Latest Developments
11.5 GenScript
11.5.1 GenScript Company Information
11.5.2 GenScript mRNA Vaccine Raw Materials Product Offered
11.5.3 GenScript mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 GenScript Main Business Overview
11.5.5 GenScript Latest Developments
11.6 Aji Bio-Pharma
11.6.1 Aji Bio-Pharma Company Information
11.6.2 Aji Bio-Pharma mRNA Vaccine Raw Materials Product Offered
11.6.3 Aji Bio-Pharma mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Aji Bio-Pharma Main Business Overview
11.6.5 Aji Bio-Pharma Latest Developments
11.7 Merck KGaA
11.7.1 Merck KGaA Company Information
11.7.2 Merck KGaA mRNA Vaccine Raw Materials Product Offered
11.7.3 Merck KGaA mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Merck KGaA Main Business Overview
11.7.5 Merck KGaA Latest Developments
11.8 Aldevron
11.8.1 Aldevron Company Information
11.8.2 Aldevron mRNA Vaccine Raw Materials Product Offered
11.8.3 Aldevron mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Aldevron Main Business Overview
11.8.5 Aldevron Latest Developments
11.9 Hongene
11.9.1 Hongene Company Information
11.9.2 Hongene mRNA Vaccine Raw Materials Product Offered
11.9.3 Hongene mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Hongene Main Business Overview
11.9.5 Hongene Latest Developments
11.10 WuXi Biologics
11.10.1 WuXi Biologics Company Information
11.10.2 WuXi Biologics mRNA Vaccine Raw Materials Product Offered
11.10.3 WuXi Biologics mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 WuXi Biologics Main Business Overview
11.10.5 WuXi Biologics Latest Developments
11.11 Asymchem
11.11.1 Asymchem Company Information
11.11.2 Asymchem mRNA Vaccine Raw Materials Product Offered
11.11.3 Asymchem mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Asymchem Main Business Overview
11.11.5 Asymchem Latest Developments
11.12 Cosychem
11.12.1 Cosychem Company Information
11.12.2 Cosychem mRNA Vaccine Raw Materials Product Offered
11.12.3 Cosychem mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Cosychem Main Business Overview
11.12.5 Cosychem Latest Developments
11.13 Novoprotein
11.13.1 Novoprotein Company Information
11.13.2 Novoprotein mRNA Vaccine Raw Materials Product Offered
11.13.3 Novoprotein mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Novoprotein Main Business Overview
11.13.5 Novoprotein Latest Developments
11.14 Vazyme
11.14.1 Vazyme Company Information
11.14.2 Vazyme mRNA Vaccine Raw Materials Product Offered
11.14.3 Vazyme mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Vazyme Main Business Overview
11.14.5 Vazyme Latest Developments
11.15 Yeasen
11.15.1 Yeasen Company Information
11.15.2 Yeasen mRNA Vaccine Raw Materials Product Offered
11.15.3 Yeasen mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Yeasen Main Business Overview
11.15.5 Yeasen Latest Developments
11.16 KACTUS
11.16.1 KACTUS Company Information
11.16.2 KACTUS mRNA Vaccine Raw Materials Product Offered
11.16.3 KACTUS mRNA Vaccine Raw Materials Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 KACTUS Main Business Overview
11.16.5 KACTUS Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂